Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound ...

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

It is made possible through a first-of-a-kind integration with Eli Lilly's direct-to-consumer website, and aims to streamline ...

Eli Lilly (LLY) reported positive Phase 3 data for its drug candidate imlunestrant as both a combination and monotherapy in ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.

Eli Lilly (LLY) concluded the recent trading session at $796.03, signifying a -0.44% move from its prior day's close.

We recently published a list of Jim Cramer’s Latest Calls: Top 10 Stocks. In this article, we are going to take a look at ...

Eli Lilly will start studying its obesity products as treatments for alcohol and drug abuse, making it the first major ...

Ro announced earlier that it is working with Eli Lilly (LLY) and Company to streamline access to Zepbound single-dose vials for Ro patients ...

Eli Lilly's Phase 3 EMBER-3 trial shows imlunestrant improves progression-free survival in advanced ER+ breast cancer ...

Global Alzheimer's Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood ...